Pharmaceutical Manufacturing
In 2023, the revenue of the pharmaceutical manufacturing segment by Fosun Pharma amounted to 30,222 million.
Fosun Pharma focuses on core therapeutic fields such as tumors (solid tumors and hematologic tumors), self-immunity, central nervous system, and chronic diseases (hepatopathy/metabolic diseases/nephropathy) through independent research and development, cooperative development, license-in, and in-depth incubation, emphasizes strengthening small molecules, antibodies/ADC, cell therapy, and RNA core technical platforms, creates an open and global innovative R&D system, actively explores the technical distribution for tumor vaccine, RNA, AI-assisted therapy, etc., and persistently enhances core R&D capabilities and pipeline value, so as to promote the R&D and commercialization of more FIC (First-in-class) and BIC (Best-in-class) products.
By the end of 2023, the company had more than 70 projects for drugs under development, including innovator drugs, biosesimilars. In 2023, the company applied for 206 patents in the pharmaceutical manufacturing segment, including 5 US patents and 11 PCT applications, with 74 patents granted.